Company Overview
Aytu BioPharma, Inc. operates as a pharmaceutical entity dedicated to the commercialization of novel therapeutics for markets within the United States and internationally, with a specific focus on prescription products designed for the treatment of attention deficit hyperactivity disorder (ADHD). The company functions within the Healthcare sector and specifically occupies the Drug Manufacturers - Specialty & Generic industry, positioning it as a specialized player rather than a broad-based generic manufacturer. Its operational scale is defined by a market capitalization of $27.91M, annual revenue of $62.64M, and an employee base of 82 individuals. These valuation and revenue figures indicate that Aytu BioPharma operates as a small-cap entity with limited market penetration relative to major pharmaceutical conglomerates, suggesting a niche focus on specific therapeutic indications rather than diversified product lines.
Financial Health
The company reported revenue of $62.64M over the trailing twelve months, yet recorded a net income of -$24,559,000, revealing a significant disconnect between top-line sales and bottom-line profitability. This substantial gap between revenue and net income highlights a cost structure where operating expenses and other deductions far outweigh gross profits, resulting in a net loss despite positive cash generation from core operations. The firm generated EBITDA of $4.03M, which contrasts sharply with the negative net income, indicating that non-operating expenses or financing costs are materially impacting the bottom line. Free cash flow stands at -$6,978,375, signaling that the company is currently burning cash to fund operations or development, which limits immediate financial flexibility and necessitates ongoing capital access. Profitability analysis shows a gross margin of 66.8%, which reflects efficient production or sourcing of goods, while the operating margin of -13.0% and profit margin of -39.0% demonstrate that high fixed costs or administrative expenses are eroding gross profits at a significant rate. The balance sheet holds $30.02M in cash against $22.10M in debt, resulting in a debt-to-equity ratio of 155.63, which suggests a highly leveraged position where equity capital is minimal relative to obligations. Although the company maintains a current ratio of 1.16, indicating that current assets slightly exceed current liabilities, this narrow liquidity buffer leaves little room for short-term financial stress or unexpected outflows. Return on equity is reported at -109.2% and return on assets at -0.2%, metrics that reveal management is currently unable to generate positive returns on the capital invested or assets held, reflecting the challenges of sustaining profitability in the current operational cycle.
Valuation Assessment
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the absence of positive earnings, while the forward P/E is calculated at 15.29, implying that the market is pricing in future earnings recovery rather than current performance. The price-to-book ratio of 1.97 indicates that the stock trades at a premium of approximately 97% above its book value, suggesting that the market assigns significant value to the company's intangible assets or future growth potential despite current losses. Alternative valuation measures include a price-to-sales ratio of 0.45 and an EV/EBITDA of 4.96, which suggest that the company is valued at less than half of its annual sales revenue, a metric often seen in biotech or specialty pharma firms that prioritize pipeline value over current profitability. The stock has traded between a 52-week high of $3.07 and a 52-week low of $0.95; without a specific current price provided in the data, the valuation range establishes a historical volatility band where the stock has fluctuated significantly over the past year. The beta value of 0.34 indicates that the stock exhibits low price volatility relative to the broader market, moving with less intensity than the overall index and potentially offering a different risk profile for portfolio diversification.
Growth & Income
Revenue growth year-over-year stands at -6.5%, while earnings growth is listed as N/A due to the negative net income position, implying that the company is currently in a contractionary phase regarding top-line sales without the benefit of earnings compounding. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it is not distributing cash to shareholders but is instead retaining all available cash flows, though currently insufficient, to fund operations without external capital. The absence of a dividend yield confirms that the company reinvests any potential earnings or utilizes cash reserves to fund its research and development efforts rather than providing income to investors. Overall, the growth and income profile is characterized by negative revenue momentum, a lack of dividend income, and a reliance on alternative valuation metrics like forward P/E and price-to-sales to assess potential future performance.